CLINICAL_TRIALS
trial_result
· 2022-02-02
Clinical Trial Update: Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer [Phase 2]
Summary
Phase 2 trial update evaluating low-dose Apatinib combined with neoadjuvant chemotherapy for early triple-negative breast cancer.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Guangdong Provincial People's Hospital | Conditions: Triple-Negative Breast Cancer | Phase 2 | Status: COMPLETED